FDA Clears First Human Trial for Age-Reversal Gene Therapy

For the first time, a therapy designed to reverse cellular aging will be tested in humans. On January 30, 2026, Life Biosciences received FDA IND (Investigational New Drug) clearance for ER-100, a gene therapy that partially rewinds the biological clock of cells. No technology targeting age reversal at the epigenetic level had crossed this regulatory threshold before.

What the FDA cleared

ER-100 uses partial epigenetic reprogramming, a technique that does not alter DNA itself but resets the way cells read their genetic instructions. Think of it as reverting a cell’s operating system to an earlier version while keeping all the hardware intact. The cell retains its identity and function but operates with the efficiency of a younger cell.

The technology relies on three of the four Yamanaka factors, the transcription proteins (Oct4, Sox2, Klf4, c-Myc) discovered by Nobel laureate Shinya Yamanaka in research that earned the 2012 Nobel Prize in Physiology or Medicine. Using all four factors reprograms a cell completely back to a stem cell state, erasing its identity. Using three allows what researchers call “partial reprogramming,” where the cell gets younger without losing what it is.

How it works in practice

ER-100 is delivered via direct injection into the eye, targeting retinal ganglion cells. The two conditions under investigation are glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy, a condition where insufficient blood flow to the optic nerve causes rapid vision loss).

A critical safety feature is built into the design. The antibiotic doxycycline acts as an on/off switch for the reprogramming genes. Administering doxycycline activates the Yamanaka factors; stopping it shuts them down. This prevents cells from reprogramming too far, a risk that could otherwise lead to loss of cell identity or uncontrolled growth.

The company behind it

Life Biosciences was cofounded by David Sinclair, the Harvard geneticist whose lab has been at the center of aging research for over two decades. Despite having fewer than 20 employees, the company secured the first FDA clearance for partial de-aging technology in humans. CEO Jerry McLaughlin called it “a transformational day for the field of partial epigenetic reprogramming.”

Patient enrollment is expected to begin within months. Phase 1 results, focused on safety, are anticipated by late 2026 or early 2027.

Why this matters beyond the eye

The trial targets vision loss, but the implications reach far beyond ophthalmology. If partial epigenetic reprogramming proves safe and effective in human retinal cells, the same mechanism could be applied to other tissues, including skin.

Preclinical evidence already supports that possibility. Animal studies have repeatedly demonstrated that partial reprogramming restores collagen production capacity in aged skin fibroblasts (the cells responsible for producing collagen), accelerates wound healing, and reverses cellular aging biomarkers. One 2023 study reported rewinding the epigenetic age of human skin fibroblasts by an average of approximately 30 years.

The practical distance between an eye injection and a skin treatment remains significant, involving different delivery methods, safety profiles, and regulatory pathways. But the principle is the same: resetting a cell’s epigenetic state to restore youthful function. If this trial demonstrates that the principle works safely in living humans, the path to skin, joint, and muscle applications becomes substantially shorter.

This is the moment when cellular age reversal moves from laboratory animals to the first human patients. The results will shape the next decade of aging science.

---